Central Serous Chorioretinopathy Associated with Tadalafil

We report a case of central serous chorioretinopathy (CSCR) associated with tadalafil, a phosphodiesterase 5 inhibitor medication. In this report, we describe a case of a 59-year-old male who presented with blurred vision in the right eye. On examination, he was noted to have serous macular, pigment epithelial detachments, and increased choroidal thickness. The diagnosis of CSCR was made, and the patient was asked to stop the offending agent. Three months after stopping tadalafil, the patient’s visual symptoms and subretinal fluid resolved. In conclusion, prescribing physicians should be aware of tadalafil’s ability to decrease vision and cause CSCR. The addition of CSCR to the list of tadalafil’s side effects should also be considered.